Breast cancer is the most commonly diagnosed cancer among women globally. Clinical development is advancing rapidly, and precision medicine, biomarker-defined patient populations, novel therapeutic modalities, and sophisticated trial designs are transforming what is possible for patients while raising the operational bar for sponsors. For biotech and emerging biopharma companies, moving from an early-stage program to regulatory approval demands expert-level understanding of the science, clinical landscape, and operational factors that determine success.
Read the full article to learn about:
- How across subtypes, the treatment paradigm is shifting, with ADCs redefining HER2-low disease and CDK4/6 inhibitors and immunotherapy moving earlier in treatment
- The challenges faced by biomarker-driven development faces challenges, including complex inclusion criteria, evolving assay strategies, and the difficulty of finding reliable predictors in triple-negative breast cancer
- Persistent enrollment and site selection challenges in one of oncology’s most competitive trial environments, including pre-screening efficiency and treatment-naïve patient scarcity
- Phase-specific development considerations, from rapid signal detection in Phase I studies to the operational discipline of multi-country registrational trials
